People with TBI may continue to improve or decline years after their injury, making it a more chronic illness, according to a study published in the June 21, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology.
AstraZeneca’s sBLA for LS-SCLC treatment gains FDA priority review
Imfinzi has a generally manageable safety profile, with no new safety signals detected during the trial. Credit: JHVEPhoto via Shutterstock. AstraZeneca has received priority review